2025
Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing
Lee K, Liu Z, Huang Q, Corrigan D, Kalsekar I, Jun T, Stolovitzky G, Oh W, Rajaram R, Wang X. Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing. JCO Clinical Cancer Informatics 2025, 9: e2400227. PMID: 40249880, PMCID: PMC12011440, DOI: 10.1200/cci-24-00227.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDistant metastasis-free survivalRecurrence-free survivalLocoregionally advanced non-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerStage I-IIIA non-small cell lung cancerNatural language processingLung cancerRecurrence-free survival ratesNon-small cell lung cancer recurrenceRisk factorsEarly-stageCox proportional hazards analysisStage IB patientsMetastasis-free survivalKaplan-Meier analysisNatural language processing systemsLikelihood of recurrenceAnalyze risk factorsProportional hazards analysisLocal/regional recurrenceRFS ratesCurative resectionStage IA
2024
Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis
Hathout L, Sherwani Z, Alegun J, Ohri N, Fields E, Shah S, Beriwal S, Horne Z, Kidd E, Leung E, Song J, Taunk N, Chino J, Huang C, Russo A, Dyer M, Li J, Albuquerque K, Damast S. Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2024, 119: 1158-1165. PMID: 38253292, DOI: 10.1016/j.ijrobp.2024.01.203.Peer-Reviewed Original ResearchRecurrence-free survivalEndometrioid endometrial adenocarcinomaMismatch repair statusAdjuvant radiation therapyOverall survivalRadiation therapyVaginal brachytherapyMismatch repair deficiencyAssociated with worse recurrence-free survivalMulti-institutional retrospective cohort studyTreated with adjuvant radiation therapyAssociated with recurrence-free survivalMultivariate analysisExternal beam radiation therapyRecurrence-free survival ratesMismatch repair deficiency statusBeam radiation therapyGrades 1 to 2Kaplan-Meier methodOutcomes of patientsMulti-institutional analysisRetrospective cohort studyCox proportional hazards modelsProportional hazards modelAdjuvant radiation
2023
Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional Analysis
Sherwani Z, Alegun J, Russo A, Damast S, Albuquerque K, Nwachukwu C, Dyer M, Fields E, Beriwal S, Horne Z, Vergalasova I, Ohri N, Taunk N, Chino J, Kidd E, Leung E, Song J, Hathout L. Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s8. DOI: 10.1016/j.ijrobp.2023.06.217.Peer-Reviewed Original ResearchEndometrioid endometrial cancerEarly-stage endometrioid endometrial cancerExternal beam radiation therapyAdjuvant radiation therapyLymphovascular space invasionOverall survivalGrade 3Radiation therapyStage IMultivariate analysisWorse RFSWorse OSEndometrial cancerUnivariate analysisMulti-institutional retrospective cohort studyFIGO 2009 stage IRecurrence-free survival ratesCox proportional hazards modelPost-surgical stagingRetrospective cohort studyKaplan-Meier methodDeep myometrial invasionFIGO grade 1Proportional hazards modelBeam radiation therapy
2021
Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?
Yoon J, Fitzgerald H, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ, Hathout L. Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? Practical Radiation Oncology 2021, 12: e123-e134. PMID: 34822999, DOI: 10.1016/j.prro.2021.10.002.Peer-Reviewed Original ResearchConceptsStage IIIC1 endometrial cancerPelvic radiation therapyOverall survivalEndometrial cancerRadiation therapySurvival outcomesFirst recurrenceHazard ratioRFS ratesCommon siteRecurrence-free survival ratesMulti-institutional retrospective studyPropensity scoreCox proportional hazards modelImproved survival outcomesKaplan-Meier methodProportional hazards modelInternational FederationNew therapeutic approachesAdjuvant chemotherapyDistant recurrenceSystemic chemotherapyImprove outcomesClinical outcomesDistant metastasisA Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaOverall survivalEndometrial carcinomaRadiation therapyAdjuvant chemotherapyAdjuvant therapyPALN recurrenceSystemic chemotherapyRFS ratesMulti-institutional retrospective cohort studyStage IIIC endometrial cancerRecurrence-free survival ratesLymph node recurrenceSequential radiation therapyAdjuvant radiation therapyRetrospective cohort studyGrade 3 tumorsAdjuvant treatment regimensKaplan-Meier methodVaginal cuff brachytherapyHigh rateSequence of treatmentChemotherapy concurrentNodal radiationNode recurrence
2020
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Ma C, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Dockter T, Korde L, Weiss A, Hunt K, Hudis C, Winer E, Partridge A, Carey L, Ellis M. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. Journal Of Clinical Oncology 2020, 38: 504-504. DOI: 10.1200/jco.2020.38.15_suppl.504.Peer-Reviewed Original ResearchHER2- BCEstrogen receptor-positive HER2-negative breast cancerClinical stage II/IIIBreast conservation surgery (BCS) ratesHER2-negative breast cancerRecurrence-free survival ratesStage II/IIIClinical stage IIPathologic complete responseWk 4Chi-square testAdjuvant chemotherapyCN1-3Neoadjuvant phasePrimary endpointAlone armPostmenopausal womenComplete responseLoading dosePM patientsBCS ratesSurgery ratesPO dailyBreast cancerLower risk
2016
Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy
Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.Peer-Reviewed Original ResearchConceptsAfrican American raceLow-risk prostate cancerAfrican American menRisk prostate cancerCaucasian manProstate cancerPathological upgradingBiochemical recurrenceFive-year recurrence-free survival ratesClinical low‐risk prostate cancerClinical low-risk diseaseRecurrence-free survival ratesCox proportional hazards analysisBiochemical recurrence outcomesEqual-access health systemLow-risk diseaseCohort of patientsLow-risk tumorsPositive surgical marginsProportional hazards analysisSearch databasesSEARCH cohortRecurrence outcomesRisk diseaseRisk tumorsIGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers
Fu T, Pappou EP, Guzzetta AA, de Freitas Calmon M, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals Of Surgery 2016, 263: 337-344. PMID: 25822686, PMCID: PMC4648704, DOI: 10.1097/sla.0000000000001204.Peer-Reviewed Original ResearchConceptsStage II colorectal cancerRisk of recurrenceIGFBP-3 methylationLymph nodesColorectal cancerHazard ratioPrimary tumorHigh riskIndependent cohortFive-year recurrence-free survival ratesRecurrence-free survival ratesHigh-risk patientsSignificant prognostic factorsIdentification of patientsProportional hazards modelIGFBP-3Prognostic factorsTumor characteristicsPredicts RecurrenceHazards modelPatientsRecurrenceSurvival rateMultivariate analysisSurgeryPathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.
Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.Peer-Reviewed Original ResearchBiochemical recurrenceAA raceCaucasian manProstate cancerAA menCaucasian raceEqual Access Regional Cancer Hospital (SEARCH) databaseClinical low-risk diseaseLow-risk prostate cancerRecurrence-free survival ratesCox proportional hazards analysisAdverse pathological findingsEqual-access health systemHigher median PSAImmediate radical prostatectomyLow-risk diseaseLow-risk tumorsPositive surgical marginsProportional hazards analysisLow-risk menAfrican American menUse of ASGleason upgradePathologic upgradingPathological upgrade
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsThe cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming
Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner B, Blonska M, Skerl S, Shao Y, Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra M, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nature Communications 2015, 6: 7530. PMID: 26179207, PMCID: PMC4507299, DOI: 10.1038/ncomms8530.Peer-Reviewed Original ResearchMeSH Keywords14-3-3 ProteinsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCell Line, TumorDisease-Free SurvivalEnergy MetabolismExoribonucleasesFemaleGene Expression Regulation, NeoplasticGene Knockout TechniquesGlutamineGlycolysisHCT116 CellsHumansMiddle AgedOrganelle BiogenesisPrognosisProteolysisProto-Oncogene Proteins c-mycUbiquitinationYoung AdultConceptsCancer metabolic reprogrammingMetabolic reprogrammingRecurrence-free survival ratesMetabolic gene expressionBreast cancer patientsCellular energy metabolismHallmarks of cancerMajor metabolic processesTumor glucose uptakeExtensive reprogrammingMetabolic programsMitochondrial biogenesisGene expressionTumorigenic transformationCancer glycolysisMolecular mechanismsReprogrammingCancer patientsMetabolic processesMetabolic shift
2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2011
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateConceptsIntensity-modulated radiotherapyLocal-regional control ratesPancreatic adenocarcinomaAdjuvant patientsDefinitive patientsControl rateSurvival rateGrade 3 late toxicityRecurrence-free survival ratesThree-dimensional conformal radiotherapyOverall survival rateProspective clinical trialsRecurrence-free survivalDurable disease controlPlanning target volumeGreater acute toxicityAcute toxicityLate toxicityOverall survivalSystemic therapyMedian agePancreatic cancerClinical trialsPrescription doseGrade 3
2010
Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression
Anees M, Horak P, El‐Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh W. Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2010, 117: 1172-1182. PMID: 21381010, DOI: 10.1002/cncr.25504.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalProstate cancer patientsTRAIL expressionProstate cancerExpression of TRAILTumor microenvironmentTissue microarrayTRAIL pathwayCancer patientsDecoy receptorRecurrence-free survival ratesDeath receptorsStromal tumor microenvironmentTumor immune surveillanceProstate cancer epitheliumMultiple tumor typesProstate cancer tissuesOverall survivalFLICE-inhibitory proteinEpithelial expressionOvarian cancerCancer epitheliumClinicopathological parametersImmune surveillanceImpact cancer survival
2007
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal Of Clinical Oncology 2007, 25: 2650-2655. PMID: 17602071, DOI: 10.1200/jco.2006.08.2271.Peer-Reviewed Original ResearchConceptsResidual invasive cancerResidual ductal carcinomaDisease-free survivalInvasive cancerResidual DCISDFS ratesNeoadjuvant chemotherapyOverall survivalComplete eradicationOS ratesDuctal carcinomaLocoregional recurrence-free survival ratesLocal recurrence-free survivalRecurrence-free survival ratesTexas M.D. Anderson Cancer CenterM.D. Anderson Cancer CenterOutcomes of patientsRate of patientsInvasive breast cancerLocal recurrence rateRecurrence-free survivalBreast cancer patientsInclusion of patientsAnderson Cancer CenterLong-term survivalEffect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo A, Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2007, 25: 530-530. DOI: 10.1200/jco.2007.25.18_suppl.530.Peer-Reviewed Original ResearchResidual invasive cancerInvasive cancerResidual DCISSurvival rateNeoadjuvant chemotherapyComplete eradicationDisease-free survival ratesLocal recurrence-free survivalRecurrence-free survival ratesUT MD Anderson Cancer CenterMD Anderson Cancer CenterResidual ductal carcinomaOutcomes of patientsPathologic complete responseRate of patientsInvasive breast cancerLocal recurrence rateOverall survival rateRecurrence-free survivalBreast cancer patientsAnderson Cancer CenterInclusion of casesPatients 78Residual invasivePreoperative chemotherapy
2001
Adenoid cystic carcinoma: A retrospective clinical review
Khan A, DiGiovanna M, Ross D, Sasaki C, Carter D, Son Y, Haffty B. Adenoid cystic carcinoma: A retrospective clinical review. International Journal Of Cancer 2001, 96: 149-158. PMID: 11410883, DOI: 10.1002/ijc.1013.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPerineural invasionNeu positivityCystic carcinomaSurvival rateOral cavity/oropharynxRecurrence-free survival ratesDistant recurrence-free survivalDistant recurrence ratesMinor gland tumorsCause-specific survivalOverall survival rateAmerican Joint CommitteeRetrospective clinical reviewSquamous cell carcinomaHigh tumor gradeTerms of survivalDecreased OSCancer criteriaBrain metastasesNerve invasionPalliative casesChart reviewMargin statusOverall survival
2000
Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix
Roberts K, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S, Sartorelli A, Fischer D, Fischer J. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix. International Journal Of Cancer 2000, 90: 206-223. PMID: 10993961, DOI: 10.1002/1097-0215(20000820)90:4<206::aid-ijc4>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaDisease-free survivalMitomycin CSurvival rateRadical radiotherapyCervix cancerActuarial disease-free survival rateLocal recurrence-free survival rateActuarial disease-free survivalAdvanced squamous cell carcinomaOpen phase III trialDisease-free survival ratesRecurrence-free survival ratesDistant recurrence-free survivalAcute radiation reactionsIII-IVA patientsIntravenous mitomycin CMild hematologic toxicityNon-hematologic toxicitiesTreatment-related deathsActuarial survival rateAdvanced stage diseasePhase III trialsMitomycin C groupRecurrence-free survivalSmoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma
Oh W, Manola J, Renshaw A, Brodkin D, Loughlin K, Richie J, Shapiro C, Kantoff P. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology 2000, 55: 31-35. PMID: 10654890, DOI: 10.1016/s0090-4295(99)00408-2.Peer-Reviewed Original ResearchConceptsClear cell renal carcinomaRecurrence-free survival ratesCell renal carcinomaStage M0Renal carcinomaSurvival rateFuhrman gradeRetrospective review of clinical recordsAlcohol useRisk factorsAssociated with overall survivalReview of clinical recordsRecurrence-free survivalMedian Follow-UpAssociated with increased mortalityOverall survival ratePrognosis of clear cell renal carcinomaRegular alcohol useAlcohol use historyT1 diseaseSuspected metastasesOverall survivalLocalized diseaseNephrectomy specimensT classification
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply